J\u30fbTEC achieved an increase in revenue and operating profit in the first quarter of fiscal year ending March 2027. Revenue is unknown, and operating profit was 240 million yen, up YoY. Contributions from significant growth in Jack OA, successful in-house development, and effects of overseas strategic investments are noted.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7774","jir_company_name":"J\u30fbTEC","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/7774-20260731-01.pdf","jir_short_summary":"J\u30fbTEC achieved an increase in revenue and operating profit in the first quarter of fiscal year ending March 2027. Revenue is unknown, and operating profit was 240 million yen, up YoY. Contributions from significant growth in Jack OA, successful in-house development, and effects of overseas strategic investments are noted.","jir_summary":"### Financial Overview\nIn the first quarter of fiscal year ending March 2027, J\u30fbTEC recorded increases in revenue and operating profit. While the specific revenue figure is unknown, operating profit reached 240 million yen, reflecting an increase from the same period last year. The main factors include significant growth in Jack OA revenue, successful in-house product development, and the effects of overseas strategic investments. Cost management and efficiency improvements have also contributed to enhanced profitability.\n\n### Future Outlook and Impact on Shareholders\nThe company plans to continue expanding overseas and its medical business, aiming for further increases in revenue and profit. Improvements in adjustment amounts and new business developments aim to strengthen the earnings foundation. For shareholders, sustained profit growth combined with expectations for dividend increases and stock price appreciation are anticipated. Management emphasizes balancing efficiency and investment to pursue sustainable growth.","jir_financial_highlights":"Revenue: Unknown (Unknown)\nOperating Profit: 240 million yen (Increase YoY)\nAdjustment Amount: Unknown (Unknown)","jir_category":"","jir_hashtags":"#J\u30fbTEC, #FinancialResults, #JapaneseStocks","jir_key_figures":"Revenue: Unknown\nOperating Profit: 240 million yen\nAdjustment Amount: Unknown","jir_meta_title":"\u3010J\u30fbTEC\u3011First Quarter Financial Results for Fiscal Year Ending March 2027 | Revenue and Profit Details","jir_meta_description":"J\u30fbTEC reported increases in revenue and operating profit in the first quarter of fiscal year ending March 2027. Contributing factors include significant growth in Jack OA and overseas strategy, with expectations for future growth.","jir_og_title":"\u3010J\u30fbTEC\u3011First Quarter Financial Results for Fiscal Year Ending March 2027 | Revenue and Profit","jir_og_description":"J\u30fbTEC achieved increases in revenue and operating profit for the first quarter of fiscal year ending March 2027, advancing its overseas expansion and medical business.","jir_og_image_url":"\/assets\/og\/company-disclosure_update.jpg","jir_chart_data_collection":"[]","ir_related_company":57771,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-92100","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n